Novo Nordisk files etavopivat for sickle cell with FDA and EMA

Image
Novo Nordisk files etavopivat for sickle cell with FDA and EMA

PLAINSBORO — November 13, 2026 -- Novo Nordisk has submitted etavopivat, a once-daily oral treatment for sickle cell disease (SCD), to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Both regulators are expected to act in 2027. The filings, a New Drug Application and a Marketing Authorization Application, rest on the Phase 3 HIBISCUS trial, which in April 2026 showed a 27% reduction in vaso-occlusive crises (VOCs) and a delay of about four months to the first VOC versus placebo.

Filings rest on a 52-week placebo-controlled trial of about 440 patients

HIBISCUS (NCT04624659) enrolled approximately 440 people aged 12 and older who had 2 to 15 VOCs in the 12 months before enrollment. The trial compared etavopivat with placebo, and participants could continue standard of care. Its endpoints are the annualized VOC rate at week 52 and the share of patients with a hemoglobin response above 1 g/dL at week 24. The submission covers adolescents and adults aged 12 and older.

The filing came about seven months after the April 2026 topline readout. Novo did not disclose the week-24 hemoglobin response result or safety data. It says detailed results will be presented at a future scientific conference and published in a peer-reviewed journal.

US and European patients make up about 2.6% of the global SCD population

Novo cites about 100,000 patients in the US and 110,000 in Europe. Together that is roughly 210,000 people, or about 2.6% of the estimated 8 million with SCD worldwide. By our calculation from Novo's regional figures, sub-Saharan Africa (5.7 million) accounts for about 71% of cases, India (1.28 million) for about 16%, and the Middle East and North Africa (618,000) for about 8%. Neither filing covers those regions.

Novo describes etavopivat as a selective activator of pyruvate kinase red blood cell isozyme (PKR). It says the mechanism reduces sickling of red blood cells. The company cites a lifespan roughly 20 years shorter for people with SCD than for the general population.

Etavopivat came to Novo through the 2022 Forma Therapeutics acquisition

The FDA has granted etavopivat Fast Track, Rare Pediatric Disease and Orphan Drug designations. The European Commission has granted Orphan Drug designation, based on a positive opinion from the EMA's Committee for Orphan Medicinal Products.

Two further studies are running. HIBISCUS 2 (NCT06612268) is a 52-week Phase 3b placebo-controlled trial with expected enrollment of 510 patients aged 12 and older. That is about 16% more than HIBISCUS's 440 and brings planned enrollment across both trials to about 950. FLORAL (NCT06609226) is an open-label extension that collects long-term safety data from patients who took part in etavopivat trials.

The FDA and the European Commission are each expected to take action on the applications in 2027.

Published by:
fairsonline_team
Products